Number of infections by Govit-19 In a survey conducted in the UK it was 65% lower for all ages after the first dose of the AstraZeneca or Pfizer vaccine, scientists say, showing the impact of the national immunization campaign in the real world.
Also read: UK dog abandonment can be contagious
This research was conducted at a time when a new and more infectious variant of the corona virus called B1.1.7 was dominating the UK, however, it was concluded that the vaccine would be as effective for the elderly with comorbidities as it was for the young. People. And healthy.
“The results in the real world are very promising,” said James Bethel, the British health minister. He said statistics show that the British vaccination program against Govt-19, one of the fastest in the world, has a “significant impact”.
The data comes from two studies that are part of the Govt-19 epidemiological study – a collaboration between the University of Oxford, the government’s Department of Health and the National Statistics Office. Two studies were published online, before being printed, and not yet reviewed.
The researchers surveyed more than 1.6 million PCR test results from 373,402 study participants between December 1, 2020 and April 3, 2021.
21 days after the first dose of the vaccine, they concluded that the rates of new Kovit-19 infections from AstraZeneca or Pfizer-Bioendech – without a second dose – were reduced by 65%. This includes a fall in 74% of symptomatic infections and a 57% drop in infections without symptoms.
The study concluded that the reduction of common and symptomatic infections after the second dose was 70% and 90%, respectively, and was similar to the effects of those who had previously experienced a Govt-19 infection.
The second study looked at antibody levels for the SARS-CoV-2 virus to see how they changed after one dose of each vaccine and two doses of Pfizer. Antibody responses to a single dose of both vaccines were slightly lower in the elderly, but results showed that they were higher in all ages after the two-dose phaser.
Copyright © Thompson Reuters.
